HIV antiretroviral drug resistance in Africa.

摘要: Highly active antiretroviral therapy (HAART) has dramatically reduced mortality and morbidity in HIV-infected persons developed countries. Although the use of HAART remains limited Africa, there are global efforts to make available these drugs several million on continent. In this review we examine impact HIV genetic diversity occurrence drug-resistance mutations among non-B subtypes, discuss implication resistant strains programs aimed at implementing treatment (ART) with respect factors that may favor treatment-acquired drug-resistant viruses, ways monitor for drug resistance, strategies limit its occurrence. We assert resistance is an inevitable consequence when providing long-term treatment, should not be seen as a limitation antiretrovirals patients resource-poor settings, but rather necessary challenge incorporated into rational design provide ART Africa.